Background: Erythema nodosum leprosum (ENL) is an immune complex-mediated reaction that clinically presents as tender erythematous evanescent nodules, mostly associated with systemic symptoms. Oral prednisolone is the drug of choice, with doses ranging from 0.5 to 1 mg/kg. Some cases may develop new lesions and systemic symptoms despite 1 mg/kg prednisolone, and in ideal practice, physicians escalate the prednisolone dose for immediate arrest of inflammation to prevent complications. However, a high dose of prednisolone has more side effects in the long term and causes more immunosuppression.
Methods: In cases of ENL, those not responding to a conventional once-daily regimen were given a split dose of oral prednisolone instead of increasing the dose. They were followed up for response, and serum cortisol was measured to see for hypothalamic-pituitary-adrenal (HPA) axis suppression.
Results: Eight cases of ENL (three nodular, three necrotic, one pustular, and one nodulcerative) had a dramatic response to split-dose therapy without any relapse and HPA axis suppression.
Conclusion: A split-dosing regimen can be a good treatment option in ENL with better control, less steroid dependency, and a lower relapse rate.
}, year = {2024}, journal = {Cureus}, publisher = {Springer Science and Business Media LLC}, issn = {2168-8184}, url = {https://www.cureus.com/articles/235018-split-dose-of-prednisolone-in-the-treatment-for-erythema-nodosum-leprosum-a-case-series?score_article=true#!/}, doi = {10.7759/cureus.60888}, language = {Eng}, }